Sanofi SA

A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech and Moderna to dismiss lawsuits filed by Bayer's Monsanto unit over their use of US Patent No. 7,741,118, a patent related to mRNA technology, with Judge William Bryson saying the companies failed to prove the patent was invalid or not infringed by their COVID-19 vaccines. Sanofi agreed to a deal worth up to $8B, including $1B upfront, with Regeneron to jointly develop four long-acting immunology therapies, led by the clinical-stage IL-13 monoclonal antibody REGN20423. China's Abogen Biosciences signed a licensing and option agreement with Novartis worth up to $7.8B, comprising a $575 million upfront payment and up to approximately $7.2 billion in potential milestone payments if all options on all programs are exercised, covering an exclusive worldwide license to Abogen's lead asset ABO2203. Jiangsu Hengrui Pharmaceuticals agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6B, with $300M upfront and the transaction expected to close in Q4 2026. Meanwhile, the S&P 500 Health Care Sector Index slipped 2.66% for the week, with Incyte down 6.93% and Regeneron down 6.71% among the top decliners, while McKesson rose 4.11% and Cardinal Health gained 3.67%.

Sanofi and Regeneron Pharmaceuticals have expanded their longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. Under the agreement, the companies will co-develop and co-commercialize four Regeneron-invented antibodies targeting IL-13, an IL-4xIL-13 bispecific, IL-4 and IL-4Rα, with one program, REGN20423, a long-acting IL-13 monoclonal antibody, currently in a phase I study for atopic dermatitis and the other three expected to enter clinical studies in 2027. Regeneron is entitled to a $1 billion upfront payment from Sanofi and up to $7 billion in additional development, regulatory and commercial milestone payments, while the two will equally share development and commercialization costs and future profits globally, with Regeneron leading research and development and Sanofi overseeing global commercial efforts. Regeneron will also have an option to include Sanofi's investigational candidate lunsekimig, a bispecific nanobody therapy targeting TSLP and IL-13, in the collaboration after completion of its phase III studies in chronic obstructive pulmonary disease, and the companies agreed to settle their prior collaboration-related litigation. The expanded collaboration builds on a more than 20-year alliance that established Dupixent as a widely used treatment for type II inflammation, with more than 1.5 million people currently receiving the drug across nine indications, and the existing profit-sharing agreement for Dupixent will remain unchanged.

French pharmaceutical giant Sanofi and U.S. biopharmaceutical company Regeneron Pharmaceuticals announced on the 1st that they will jointly develop four new drugs under a contract worth up to $8 billion and will settle their previous litigation. Sanofi will pay $1 billion upfront and an additional $7 billion upon achieving milestones. The two companies will split the development costs and future profits of the four new drugs, with Regeneron leading research and development and Sanofi handling global sales if the drugs are approved. The four new drugs include a candidate treatment for atopic dermatitis, which is currently in early-stage clinical trials. Sanofi's new Chief Executive Officer, Belén Garijo, said on an investor conference call that "mutual trust will guide this expanded partnership," adding that the partnership includes clear divisions of roles and accountability for both companies.

Regeneron shares fell 4% after the biotech company expanded its immunology alliance with Sanofi on terms that left the economics of its blockbuster drug Dupixent untouched. Under the deal, Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in development, regulatory, and commercial milestones for four next-generation, long-acting antibodies, with the two drugmakers splitting global development costs, commercialization expenses, and future profits equally. The agreement settles prior litigation but leaves the existing Dupixent profit-sharing terms unchanged, disappointing investors who had hoped a renegotiation would yield better economics on the franchise; nearly a quarter of investors surveyed by RBC Capital sought more constructive terms, according to Investing.com. Sanofi shares rose roughly 2% in European trading, according to Reuters, while Regeneron reversed an early morning gain, later trading at $736.56, down 2.9% from the previous close. Regeneron is down 5.1% since the start of the year and trades 13.6% below its 52-week high of $852.03.

Sanofi's new and acquired drugs are emerging as a broadening growth base beyond its flagship immunology medicine Dupixent, with sales of those newer products rising 48.3% at constant exchange rates to €1.3 billion in the second quarter, led by Altuviiio, Ayvakit and Sarclisa. Dupixent, marketed in partnership with Regeneron, remains the company's primary growth engine and accounted for roughly 42% of Sanofi's first-half 2026 revenues. Altuviiio achieved blockbuster sales in 2025, while Ayvakit, added through the Blueprint Medicines acquisition, is expected to become the next blockbuster drug in 2026, and Beyfortus, developed with AstraZeneca, reached blockbuster sales in its first full year in 2024. Sanofi now expects its Pharma launches to generate approximately €10 billion of annual sales by 2030, compared with about €25 billion for Dupixent, as it positions the newer medicines to gradually reduce reliance on its top-selling drug. The Zacks Consensus Estimate for 2026 earnings has risen from $4.96 per share to $5.07 per share over the past 60 days, while 2027 estimates climbed from $5.18 to $5.29 per share, and Sanofi stock has fallen 15.5% year to date against an 11.7% gain for the industry.

Regeneron Pharmaceuticals executives told Bernstein analyst Jeffrey Walch that EYLEA HD, Dupixent and Libtayo each reached all-time quarterly net sales, with EYLEA HD accounting for roughly 60% of EYLEA franchise net sales in the second quarter. Chief financial officer Chris Fenimore said Regeneron expects sequential demand growth for EYLEA in the low- to mid-teens percentage range in both the third and fourth quarters despite additional biosimilar competition in the 2-milligram market, and that the company paid off its Sanofi development balance in the second quarter, a move expected to lift earnings from the Sanofi collaboration beginning in the third quarter. Dupixent is annualizing at approximately $24 billion in sales, including approximately $18 billion in the U.S., while Libtayo sales rose more than 30% year over year and now rank second in both new-to-brand and total share in U.S. lung cancer. On the pipeline, the FDA action date for cemdisiran in generalized myasthenia gravis is in November, registration-enabling PNH data are expected in the fourth quarter, and further readouts are anticipated in MASH, Factor XI and melanoma. Regeneron repurchased approximately $2 billion of stock in the first half, including $1.2 billion in the second quarter, and pays roughly $400 million annually under a dividend program begun in 2025.

Teva Pharmaceutical Industries said its "Pivot to Growth" strategy has entered its second phase, with management pointing to branded-medicine momentum, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet. Speaking at a Morgan Stanley event, President and Chief Executive Officer Richard Francis said the strategy, launched in 2023, rests on four pillars: delivering on the growth engine, stepping up innovation, creating a generics powerhouse, and focusing the business and capital allocation. Francis said Teva has cut debt and secured investment-grade ratings from all three major agencies more than a year ahead of its projection, completed an oversubscribed refinancing in the prior week, and converted ADS shares into ordinary shares to broaden investor access. He reiterated confidence that AUSTEDO can eventually exceed $3 billion in sales, ahead of the prior $2.5 billion target, and said AJOVY is approaching the $1 billion threshold faster than expected, while UZEDY and long-acting olanzapine together represent a $1.5 billion to $2 billion opportunity. Teva has 11 biosimilars on the market and expects to add roughly nine more by the end of the decade, and Francis said the company is on track to exceed its $800 million biosimilars target for 2027 a year early. Chief Medical Officer Eric Hughes said the TL1A therapy duvakitug, developed with Sanofi for ulcerative colitis and Crohn's disease, showed the highest phase 2 results reported for the class, and that ecopipam, a first-in-class D1 antagonist for Tourette's disease, received priority review with a potential launch in the first half of 2027.

DelveInsight projects the ulcerative colitis market across the seven major markets—the US, EU4, UK, and Japan—will grow from approximately USD 9.4 billion in 2025 at a CAGR of 7.6% through 2036, driven by novel targeted therapies and a robust pipeline of late-stage candidates. Among these, Abivax's obefazimod, a first-in-class oral miR-124 enhancer, met its primary endpoint in Phase III ABTECT induction studies, with a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8. Merck's tulisokibart, acquired via Prometheus Biosciences, achieved clinical remission in the Phase 3 ATLAS-UC study, while Roche's afimkibart, from its $7.1 billion Telavant acquisition, showed a 35% remission rate in Phase IIb TUSCANY-2. Johnson & Johnson and Protagonist Therapeutics' icotrokinra, a first-in-class oral IL-23 receptor antagonist, met its primary endpoint in the Phase 2b ANTHEM-UC trial, and Teva and Sanofi's duvakitug, backed by a $400 million Blackstone funding deal, is in Phase III. These therapies target unmet needs in moderate-to-severe disease, with the market shifting toward IL-23 inhibitors and oral advanced therapies, though biosimilars and established anti-TNFs remain widely used.

Novavax's partners have received approvals for the XFG-adapted Nuvaxovid vaccine for the 2026-2027 vaccination season in the U.S., European Union, and Japan, positioning the company to earn royalties on net sales in these markets. The approvals, announced August 28, 2026, cover the protein-based, non-mRNA vaccine, which has demonstrated a favorable tolerability profile in Sanofi's Phase 4 COMPARE study. Novavax's largest partner, Sanofi, will lead commercial activities in most major markets, including an expanded U.S. campaign and launches in Germany, Canada, and other international markets from 2026 onward. Takeda, which commercializes Nuvaxovid in Japan, saw the vaccine become the second-most used COVID-19 vaccine there in the 2025-2026 season, with delivery volumes and site numbers increasing significantly year over year. Under the collaboration and license agreements, Novavax is eligible for ongoing royalties and annual milestones tied to regulatory approvals, without carrying its own commercial infrastructure.

The global cytotoxic drugs market is projected to grow from $16.21 billion in 2026 to $21.06 billion by 2031, at a compound annual growth rate of 5.37%, according to a new report from ResearchAndMarkets.com. Rising cancer incidence, earlier diagnosis, expanded reimbursement, and growing demand in emerging economies are driving the market. In 2025, the market was valued at $15.38 billion, with parenteral drugs holding a 68.87% share, while oral drugs are expected to grow faster at an 8.79% CAGR. Alkylating agents led with a 30.10% share in 2025, but antimetabolites are forecast to grow fastest at 7.02% CAGR. North America accounted for 42.15% of revenue in 2025, while Asia-Pacific is projected to grow at 10.07% CAGR, supported by China's approval of 228 drugs in 2024, 37% of which were antineoplastics. Key players include Pfizer, Roche, Novartis, AstraZeneca, and Sanofi.

Several biotech stocks reached 52-week highs on August 7, 2026, driven by quarterly results and clinical advancements. Delcath Systems surged over 22% to $15.62 after reporting second-quarter net revenues of $29.1 million, up from $24.2 million a year earlier, with HEPZATO product revenue growing about 30% to $27.1 million across roughly 31 active treatment centers. Alto Neuroscience rose to a 52-week high of $29.48 following last month's registered direct offering that raised an estimated $100 million to advance its lead candidate ALTO-207 toward a Phase 3 trial. Hemab Therapeutics hit $53.60 after positive Phase 2 data showed Sutacimig reduced the mean annualized treated bleeding rate by 84% in Glanzmann thrombasthenia and Factor VIII deficiency, alongside encouraging interim Phase 2 results for HMB-002 in Von Willebrand's disease. Monopar Therapeutics reached $124.31 on the back of positive Phase 3 results for ALXN1840 in Wilson disease, which earned a Rare Pediatric Disease voucher from the FDA, with an NDA submission planned by mid-2026. Nurix Therapeutics climbed to $25.49 after receiving a $10 million milestone payment from Sanofi for the Phase 1 initiation of NX-3911 and announcing with Roche the first patient enrolled in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in relapsed/refractory chronic lymphocytic leukemia.

Novavax raised its full-year 2026 revenue guidance to between $235 million and $275 million, driven by strong demand for its Matrix-M adjuvant from commercial partners. The company reported a net loss of $53 million in the second quarter on total revenue of $57 million, a sharp decline from $239 million a year earlier due to the absence of one-time milestone payments. Novavax is on track to reduce operating expenses by approximately 90% from peak levels and reiterated its goal of reaching non-GAAP profitability as early as 2028. The Sanofi partnership is advancing, with Sanofi in advanced regulatory discussions for a Phase 3 combination COVID-19/influenza vaccine study, which would trigger a $125 million milestone payment. Novavax also expects a $75 million manufacturing tech transfer milestone from Sanofi by mid-2027, extending its cash runway into 2029.

Nurix Therapeutics announced a $10 million milestone payment from Sanofi triggered by the first-in-human trial of an oral STAT6 degrader, bringing total receipts under that collaboration to about $139 million. The company also enrolled the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia, conducted in partnership with Roche. The Sanofi deal leaves Nurix eligible for roughly $453 million in additional milestones plus potential royalties, while the Roche-partnered study marks a move into registrational testing. Both programs advance Nurix's clinical pipeline in targeted protein degradation and signal that large pharmaceutical partners are committing resources to its drug candidates.

The European Commission has approved Sanofi’s MenQuadfi vaccine for use in infants aged six weeks and older, expanding protection against invasive meningococcal disease caused by serogroups A, C, W and Y. MenQuadfi was previously authorized in the EU only for individuals 12 months and older, and the new indication introduces infant dosing schedules aligned with routine pediatric immunization programs. The approval is supported by the MET58 pivotal study, which evaluated immunogenicity, safety and tolerability in more than 6,000 infants across 11 countries. The decision broadens Sanofi’s vaccine portfolio and gives healthcare providers an additional option to protect infants against a rapidly progressing disease associated with high mortality and long-term complications.

Sanofi reported €1,031 million of intangible asset impairments for the second quarter of 2026 and completed a €1,009 million share buyback covering 1.05% of its share count. The most followed narrative points to a fair value of €96.70, implying the stock is 23% undervalued compared with its last close of €74.47. The valuation case rests on steady top-line growth, rising margins, and a lower future earnings multiple, supported by innovative product launches and a strong R&D pipeline that includes multiple Phase III readouts through 2026 and expansion of biologics such as Dupixent and amlitelimab. Key risks include intensifying pricing pressure in vaccines and potential failures of late-stage pipeline assets.

Alnylam Pharmaceuticals reported that its drug Amvuttra exceeded $1 billion in global net product revenues in a single quarter for the first time, reaching $1.03 billion in the second quarter of 2026. Total global net product revenues were approximately $1.2 billion, a 74% increase compared to the same period last year. The company revised its full-year 2026 total net product revenue guidance to a range of $4.7 billion to $5.1 billion, citing a normalization of second-line demand growth. Non-GAAP operating income more than tripled to $318 million, while gross margin on product sales declined to 75%, down four percentage points year-over-year due to higher royalties payable to Sanofi. Alnylam also announced a strategic collaboration with B1 for exclusive commercialization and distribution rights for Amvuttra in mainland China and Macau.

The inflammatory bowel disease market across the seven major markets was valued at USD 21 billion in 2025, with the United States accounting for the largest share. The total number of incident cases of inflammatory bowel disease in the seven major markets was around 181 million in 2025. Growth is being fueled by the rising prevalence of Crohn's disease and ulcerative colitis, increased adoption of advanced biologic therapies, and the emergence of novel mechanisms of action targeting IL-23, TL1A, and S1P pathways. Key pipeline candidates include Abivax's ABX464, Merck's Tulisokibart, RedHill Biopharma's RHB-204, and Teva Pharmaceuticals and Sanofi's duvakitug, among others. The anticipated launch of these next-generation therapies is expected to reshape the treatment landscape and address unmet needs in biologic-refractory patients.

Regeneron beat Wall Street estimates for second-quarter revenue and profit, driven by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Global net sales of Dupixent, recorded by partner Sanofi, increased 38% to about $6 billion, surpassing estimates of $5.34 billion. Quarterly U.S. sales of the high-dose Eylea rose 52% to $596 million, while the lower-dose version faced competitive pressures. The company fully repaid the Sanofi Development Balance, which RBC Capital Markets analyst Brian Abrahams said should improve margins and make second-half numbers look much better. Quarterly revenue rose 17% to $4.29 billion, exceeding estimates of $3.82 billion, and non-GAAP adjusted profit was $14.29 per share, beating the estimate of $10.26.

Sanofi, the French pharmaceutical company, offers a 5.6% dividend yield and a total shareholder yield approaching 11% when including stock buybacks. Its top drug Dupixent saw first-quarter sales grow 31% year over year, driving overall sales up 13.6%. The stock trades at a forward price-to-earnings ratio of 9, below its five-year average of 11, and has fallen nearly 15% over the past year. Sanofi also reported five regulatory approvals in immunology during the quarter and has a pipeline of drugs in development that could offset future patent expirations.

Teva Pharmaceutical Industries' shift from generic to branded drugs has driven an 85% share price surge over the past 12 months, and its pipeline candidate duvakitug could fuel another 50% rally. Branded drugs like Austedo, Ajovy, and Uzedy are growing sales at mid-double-digit rates, while generics now account for just over half of total revenue. Management expects 2026 earnings per share between $1.91 and $2.11, down from $2.65 in 2025 due to the dilutive impact of the Emalex Biosciences acquisition, but forecasts a 30% increase in operating profit and adjusted EBITDA starting next year. Duvakitug, co-developed with Sanofi for ulcerative colitis and Crohn's disease, is entering phase 3 trials after promising phase 2b results, with peak annual sales projected at $2 billion to $5 billion. With the stock trading at less than 10 times estimated 2027 earnings, further progress on duvakitug could trigger another major rally.

Scribe Therapeutics surged 67% on Friday after raising $128.7 million in an upsized initial public offering. The Alameda, California-based clinical-stage gene therapy developer opened at $25 per share, significantly above its $15 IPO price, after selling 8.58 million shares, up from the initially marketed 7.15 million shares at between $13 and $15 each. The first-day trading level gave the company a market value of approximately $440.3 million. Sanofi SA agreed through affiliates to purchase about $7.5 million of shares at the IPO price in a concurrent private placement, while existing backer Eli Lilly indicated interest in owning up to 11% of the company post-offering. Scribe, which is evaluating gene-editing technologies for atherosclerotic cardiovascular disease and expects initial trial data in the first half of 2027, reported a net loss of $17.4 million on collaboration revenue of $2.2 million for the three months ended March 31. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo led the IPO.

Aqemia and Sanofi have expanded their multi-year research collaboration with the nomination of a new therapeutic target and an additional milestone payment. The partnership, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. Aqemia uses its proprietary physics-based generative AI platform, Qemi, to design novel molecules for Sanofi's targets, while Sanofi leads wet lab research, development, and commercialization. The collaboration now spans teams in Paris, London, Boston, and Frankfurt, and the new target nomination reflects growing confidence in the platform's ability to tackle difficult, first-in-class projects.

Pfizer, Novo Nordisk, and Sanofi are highlighted as high-yield dividend stocks to buy and hold despite recent challenges. Pfizer offers a forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline in oncology and weight loss. Novo Nordisk, with a 3.6% forward yield, remains a leader in diabetes and weight loss markets and is advancing candidates such as zenagamtide and CagriSema, while also diversifying into rare blood diseases. Sanofi provides a 5.6% forward yield, driven by the strong performance of Dupixent and pipeline prospects like frexalimab, which could generate over $1 billion in peak annual sales.

The global vaccine sales market is projected to grow from US$76.40 billion in 2026 to US$141.40 billion by 2036, expanding at a compound annual growth rate of 6.3%. Growth is supported by rising infectious disease prevalence, broader government-funded immunisation programmes in low- and middle-income countries, and sustained investment in mRNA, viral vector, DNA and needle-free vaccine technologies. Platform-based technologies are enabling developers to pursue multiple disease targets, with programmes such as Moderna and Merck's mRNA-4157 illustrating the expanding role of mRNA in oncology. In December 2025, the Coalition for Epidemic Preparedness Innovations committed up to US$54.3 million to support a Phase III trial of Moderna's mRNA-based H5 pandemic influenza vaccine candidate, advancing the first mRNA influenza vaccine into pivotal-stage development. The market remains sensitive to U.S. tariff policies and supply-chain pressures, prompting companies to localise manufacturing and diversify suppliers. Key players include GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca and Serum Institute of India, with the report profiling 21 companies in total.

Sanofi stock may be undervalued by about 21% following US FDA approval of Sarclisa Escena, a subcutaneous multiple myeloma treatment that can be administered via on-body injector or manual injection. The most widely followed fair value estimate stands at €96.70 per share, well above the recent price of €76.23, even as the stock has slipped 4.94% over the past 90 days and 7.40% year-to-date. Supporters point to Sanofi's innovative pipeline, including Dupixent and amlitelimab, and multiple Phase III readouts through 2026 as drivers of long-term sales and earnings. Risks include vaccine pricing pressure and mixed late-stage trial results that could undermine the upbeat valuation case.

The US Food and Drug Administration has approved Sanofi’s subcutaneous Sarclisa Escena for all existing multiple myeloma indications of the intravenous formulation, making it the first anticancer treatment administered through an on-body injector. The approval covers use in combination with standard-of-care regimens and is supported by the pivotal IRAKLIA phase 3 study, which showed comparable efficacy and safety to intravenous Sarclisa, with significantly shorter treatment time and fewer infusion-related reactions. In the IRAKLIA study, Sarclisa Escena via the CirCLIQ on-body injector combined with pomalidomide and dexamethasone achieved a 71.1% objective response rate versus 70.5% for the intravenous arm, while systemic administration reactions occurred in 1.5% of patients compared to 25% with intravenous infusion. The on-body injector, developed using Enable Injections’ enFuse platform, uses a retractable 30-gauge needle and is designed to deliver high-volume medicines subcutaneously with the push of a button, potentially reducing physical burden on nurses and allowing more patient interaction. Sarclisa is approved in nearly 60 countries and has been prescribed to more than 70,000 patients worldwide.